| The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. | |
| | |
MedLine Citation:
|
PMID: 18207317 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: Intravesical chemotherapy has been studied in randomized clinical trials for >30 yr; however, the optimal schedule and duration of treatment are unknown. The objective is to determine the effect of schedule and duration of intravesical chemotherapy on recurrence in patients with stage Ta T1 bladder cancer. METHODS: A systematic review was conducted of the published results of randomized clinical trials that compared intravesical instillations with respect to their number, frequency, timing, duration, dose, or dose intensity. RESULTS: One immediate instillation after transurethral resection (TUR) is recommended in all patients. In low-risk patients, no further treatment is recommended before recurrence. In patients with multiple tumors, one immediate instillation is insufficient treatment. Additional instillations may further reduce the recurrence rate; however, no recommendations can be made concerning their optimal duration. A short intensive schedule of instillations within the first 3-4 mo after an immediate instillation may be as effective as longer-term treatment schedules (grade C). Instillations during > or =1 yr in intermediate-risk patients seem advisable only when an immediate instillation has not been given (grade C). Higher drug concentrations and optimization of the drug's concentration in the bladder may provide better results (grade C). CONCLUSIONS: The optimal schedule and duration of intravesical chemotherapy after an immediate instillation remain unknown. Future studies should focus on the eradication of residual disease after TUR and the prevention of late recurrences. |
| | |
Authors:
|
Richard J Sylvester; Willem Oosterlinck; J Alfred Witjes |
Related Documents
:
|
10074727 - Squamous cell carcinoma of the bladder: a ten-year retrospective study. 6821587 - Ct staging of bladder carcinoma. 15057157 - Tolerance of radiotherapy and chemotherapy in elderly patients with bladder cancer. 9372877 - Primary transitional cell carcinoma in vesical diverticula. 16949767 - Frequency and characteristics of docetaxel-induced radiation recall phenomenon. 12429637 - Prognostic score of gastric cancer determined by cdna microarray. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review Date: 2008-01-15 |
Journal Detail:
|
Title: European urology Volume: 53 ISSN: 0302-2838 ISO Abbreviation: Eur. Urol. Publication Date: 2008 Apr |
Date Detail:
|
Created Date: 2008-02-26 Completed Date: 2008-06-26 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 7512719 Medline TA: Eur Urol Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 709-19 Citation Subset: IM |
Affiliation:
|
EORTC Data Center, Brussels, Belgium. richard.sylvester@eortc.be <richard.sylvester@eortc.be> |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Intravesical Antineoplastic Agents / administration & dosage* Chi-Square Distribution Drug Administration Schedule Humans Neoplasm Recurrence, Local / prevention & control Neoplasm Staging Randomized Controlled Trials as Topic Risk Factors Time Factors Urinary Bladder Neoplasms / drug therapy* |
| Grant Support | |
ID/Acronym/Agency:
|
5U10 CA11488-37/CA/NCI NIH HHS; U10 CA011488-37/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrenc...
Next Document: Aspirin-associated intracerebral hemorrhage in a patient with CADASIL.